Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0RD5W
|
|||
| Former ID |
DAP001108
|
|||
| Drug Name |
Hyoscyamine
|
|||
| Synonyms |
L-Hyoscyamine; hyoscyamine; 101-31-5; (-)-Hyoscyamine; Daturine; Duboisine; (-)-Atropine; L-Tropine tropate; (S)-Atropine; (S)-(-)-Hyoscyamine; Hyoscyamine (L); UNII-PX44XO846X; Tropine, (-)-tropate; Levbid; PX44XO846X; Levsinex SR; CHEBI:17486; Hyoscyamine, l-; [3(S)-endo]-alpha-(hydroxymethyl)benzeneacetic acid 8-methyl-8-azabicyclo[321]oct-3-yl ester; (2S)-(1R,5S)-8-Methyl-8-azabicyclo[321]octan-3-yl 3-hydroxy-2-phenylpropanoate; (1R,5S)-8-METHYL-8-AZABICYCLO[321]OCT-3-YL (2R)-3-HYDROXY-2-PHENYLPROPANOATE; Hyocyamine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Gastrointestinal disease [ICD-11: DE2Z] | Approved | [1] | |
| Therapeutic Class |
Antiarrhythmic Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H23NO3
|
|||
| Canonical SMILES |
CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3
|
|||
| InChI |
1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15?,16-/m1/s1
|
|||
| InChIKey |
RKUNBYITZUJHSG-VFSICIBPSA-N
|
|||
| CAS Number |
CAS 101-31-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
4651, 814306, 841226, 7837579, 7847181, 7978742, 8144950, 10258016, 11533003, 16376693, 24890401, 24890659, 26754302, 29215197, 33498346, 36511844, 46476231, 46507540, 47359794, 48253833, 48413242, 48415591, 49857189, 53789078, 56313665, 56422449, 57352393, 75150730, 85788924, 85856317, 92308692, 93576972, 95156767, 104098724, 104169991, 104171350, 111677788, 113474904, 117475976, 118260686, 121362578, 124558762, 124799783, 124883031, 124883032, 124883033, 124883034, 129143706, 131408727, 134337687
|
|||
| ChEBI ID |
CHEBI:17486
|
|||
| ADReCS Drug ID | BADD_D01114 | |||
| SuperDrug ATC ID |
A03BA03
|
|||
| SuperDrug CAS ID |
cas=000101315
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Muscarinic acetylcholine receptor M5 (CHRM5) | Target Info | Antagonist | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Cholinergic synapse | ||||
| Regulation of actin cytoskeleton | ||||
| Panther Pathway | Alzheimer disease-amyloid secretase pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Reactome | Muscarinic acetylcholine receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| Calcium Regulation in the Cardiac Cell | ||||
| Regulation of Actin Cytoskeleton | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313. | |||
| REF 2 | Reconstitution of the purified porcine atrial muscarinic acetylcholine receptor with purified porcine atrial inhibitory guanine nucleotide binding protein. Biochemistry. 1987 Dec 15;26(25):8175-82. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.